Drug Trial Radar · NCT06465303
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jul 16, 2024
Primary completion
Jul 2, 2026
Study completion Jul 2, 2026
Sponsor
- Lead sponsor
- ResoTher PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).
Conditions
- ST Elevation Myocardial Infarction
Interventions
RTP-026Drug
Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
PlaceboDrug
Intervention is for each subject administered as three 30-minutes infusions of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Cardiac Troponin T (cTNT)Time frame: 24 hours
- Change in Creatinine kinase-MB (CK-MB)Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hjertecenteret, Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.